vs
Side-by-side financial comparison of DaVita (DVA) and Freeport-McMoRan (FCX). Click either name above to swap in a different company.
Freeport-McMoRan is the larger business by last-quarter revenue ($5.3B vs $3.6B, roughly 1.5× DaVita). Freeport-McMoRan runs the higher net margin — 10.7% vs 6.5%, a 4.3% gap on every dollar of revenue. On growth, DaVita posted the faster year-over-year revenue change (12.3% vs -10.4%). Over the past eight quarters, DaVita's revenue compounded faster (6.6% CAGR vs -7.9%).
DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona. The company is the world's largest producer of molybdenum, a major copper producer and operates the world's largest gold mine, the Grasberg mine in Papua, Indonesia.
DVA vs FCX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $5.3B |
| Net Profit | $234.2M | $565.0M |
| Gross Margin | — | 12.4% |
| Operating Margin | 15.5% | 15.4% |
| Net Margin | 6.5% | 10.7% |
| Revenue YoY | 12.3% | -10.4% |
| Net Profit YoY | 43.8% | -21.6% |
| EPS (diluted) | $3.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.6B | $5.3B | ||
| Q3 25 | $3.4B | $6.8B | ||
| Q2 25 | $3.4B | $7.5B | ||
| Q1 25 | $3.2B | $5.6B | ||
| Q4 24 | $3.3B | $5.9B | ||
| Q3 24 | $3.3B | $6.7B | ||
| Q2 24 | $3.2B | $6.4B |
| Q1 26 | $234.2M | — | ||
| Q4 25 | $234.2M | $565.0M | ||
| Q3 25 | $150.3M | $1.2B | ||
| Q2 25 | $199.3M | $1.5B | ||
| Q1 25 | $162.9M | $793.0M | ||
| Q4 24 | $259.3M | $721.0M | ||
| Q3 24 | $214.7M | $1.2B | ||
| Q2 24 | $222.7M | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 29.2% | ||
| Q2 25 | — | 34.2% | ||
| Q1 25 | — | 24.3% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 30.0% | ||
| Q2 24 | — | 31.5% |
| Q1 26 | 15.5% | — | ||
| Q4 25 | 15.5% | 15.4% | ||
| Q3 25 | 14.8% | 28.9% | ||
| Q2 25 | 15.9% | 32.3% | ||
| Q1 25 | 13.6% | 23.4% | ||
| Q4 24 | 17.2% | 21.1% | ||
| Q3 24 | 16.4% | 29.0% | ||
| Q2 24 | 15.9% | 32.0% |
| Q1 26 | 6.5% | — | ||
| Q4 25 | 6.5% | 10.7% | ||
| Q3 25 | 4.4% | 18.3% | ||
| Q2 25 | 5.9% | 20.6% | ||
| Q1 25 | 5.1% | 14.2% | ||
| Q4 24 | 7.9% | 12.3% | ||
| Q3 24 | 6.6% | 18.5% | ||
| Q2 24 | 7.0% | 20.0% |
| Q1 26 | $3.22 | — | ||
| Q4 25 | $3.22 | — | ||
| Q3 25 | $2.04 | $0.46 | ||
| Q2 25 | $2.58 | $0.53 | ||
| Q1 25 | $2.00 | $0.24 | ||
| Q4 24 | $3.08 | — | ||
| Q3 24 | $2.50 | $0.36 | ||
| Q2 24 | $2.50 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $700.7M | $3.8B |
| Total DebtLower is stronger | $10.2B | $9.4B |
| Stockholders' EquityBook value | $-651.1M | $18.9B |
| Total Assets | $17.5B | $58.2B |
| Debt / EquityLower = less leverage | — | 0.50× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $700.7M | — | ||
| Q4 25 | $700.7M | $3.8B | ||
| Q3 25 | $736.5M | $4.3B | ||
| Q2 25 | $739.4M | $4.5B | ||
| Q1 25 | $511.9M | $4.4B | ||
| Q4 24 | $846.0M | $3.9B | ||
| Q3 24 | $1.1B | $5.0B | ||
| Q2 24 | $437.2M | $5.3B |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $10.2B | $9.4B | ||
| Q3 25 | $10.2B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $9.6B | $9.4B | ||
| Q4 24 | $9.2B | $8.9B | ||
| Q3 24 | $9.3B | $9.7B | ||
| Q2 24 | $8.5B | $9.4B |
| Q1 26 | $-651.1M | — | ||
| Q4 25 | $-651.1M | $18.9B | ||
| Q3 25 | $-571.9M | $18.7B | ||
| Q2 25 | $-369.6M | $18.2B | ||
| Q1 25 | $-267.1M | $17.7B | ||
| Q4 24 | $121.1M | $17.6B | ||
| Q3 24 | $386.7M | $17.5B | ||
| Q2 24 | $632.9M | $17.4B |
| Q1 26 | $17.5B | — | ||
| Q4 25 | $17.5B | $58.2B | ||
| Q3 25 | $17.6B | $56.8B | ||
| Q2 25 | $17.5B | $56.5B | ||
| Q1 25 | $17.1B | $56.0B | ||
| Q4 24 | $17.3B | $54.8B | ||
| Q3 24 | $17.5B | $55.4B | ||
| Q2 24 | $17.0B | $54.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | 75.76× | 0.51× | ||
| Q3 24 | 23.95× | 0.55× | ||
| Q2 24 | 13.35× | 0.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $693.0M |
| Free Cash FlowOCF − Capex | — | $-312.0M |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 19.1% |
| Cash ConversionOCF / Net Profit | — | 1.23× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $693.0M | ||
| Q3 25 | $841.5M | $1.7B | ||
| Q2 25 | $324.2M | $2.2B | ||
| Q1 25 | $180.0M | $1.1B | ||
| Q4 24 | $547.6M | $1.4B | ||
| Q3 24 | $810.4M | $1.9B | ||
| Q2 24 | $798.8M | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | $395.3M | $-312.0M | ||
| Q3 25 | $675.4M | $608.0M | ||
| Q2 25 | $203.1M | $934.0M | ||
| Q1 25 | $36.8M | $-114.0M | ||
| Q4 24 | $377.0M | $197.0M | ||
| Q3 24 | $671.4M | $673.0M | ||
| Q2 24 | $674.1M | $840.0M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | -5.9% | ||
| Q3 25 | 19.7% | 8.9% | ||
| Q2 25 | 6.0% | 12.4% | ||
| Q1 25 | 1.1% | -2.0% | ||
| Q4 24 | 11.4% | 3.4% | ||
| Q3 24 | 20.6% | 10.1% | ||
| Q2 24 | 21.2% | 13.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 19.1% | ||
| Q3 25 | 4.9% | 15.5% | ||
| Q2 25 | 3.6% | 16.8% | ||
| Q1 25 | 4.4% | 21.0% | ||
| Q4 24 | 5.2% | 21.1% | ||
| Q3 24 | 4.3% | 17.9% | ||
| Q2 24 | 3.9% | 17.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.31× | 1.23× | ||
| Q3 25 | 5.60× | 1.33× | ||
| Q2 25 | 1.63× | 1.42× | ||
| Q1 25 | 1.10× | 1.33× | ||
| Q4 24 | 2.11× | 1.99× | ||
| Q3 24 | 3.77× | 1.51× | ||
| Q2 24 | 3.59× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVA
Segment breakdown not available.
FCX
| Morenci | $2.5B | 47% |
| Grasberg Segment | $964.0M | 18% |
| Copper In Concentrates | $934.0M | 18% |
| Molybdenum | $541.0M | 10% |
| Gold | $388.0M | 7% |
